SCM
ALLO icon

Sterling Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Sterling Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8K Sell
5,249
-3,617
-41% -$7.25K ﹤0.01% 2244
2025
Q4 		$12.1K Sell
8,866
-1,596
-15% -$2.1K ﹤0.01% 2508
2025
Q3 		$13K Buy
10,462
+6,836
+189% +$8.15K ﹤0.01% 2351
2025
Q2 		$4.1K Buy
3,626
+1,411
+64% +$1.88K ﹤0.01% 2619
2025
Q1 		$3.23K Sell
2,215
-1,897
-46% -$3.58K ﹤0.01% 2377
2024
Q4 		$8.76K Buy
4,112
+3,663
+816% +$9.03K ﹤0.01% 2225
2024
Q3 		$1.26K Buy
+449
New +$1.2K ﹤0.01% 2411

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return